BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34406181)

  • 1. Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma.
    Boursier C; Perrin M; Bordonne M; Campidelli A; Verger A
    Clin Nucl Med; 2022 Feb; 47(2):e152-e153. PubMed ID: 34406181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Impact of 18F-FDG PET/CT in Patients With Aggressive B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T Cells.
    Sesques P; Tordo J; Ferrant E; Safar V; Wallet F; Dhomps A; Brisou G; Bouafia F; Karlin L; Ghergus D; Golfier C; Lequeu H; Lazareth A; Vercasson M; Hospital-Gustem C; Schwiertz V; Choquet M; Sujobert P; Novelli S; Mialou V; Hequet O; Carras S; Fouillet L; Lebras L; Guillermin Y; Leyronnas C; Cavalieri D; Janier M; Ghesquières H; Salles G; Bachy E
    Clin Nucl Med; 2021 Aug; 46(8):627-634. PubMed ID: 34115706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Predicting the Adverse Effects of Chimeric Antigen Receptor T Cell Therapy in Patients with Non-Hodgkin Lymphoma.
    Wang J; Hu Y; Yang S; Wei G; Zhao X; Wu W; Zhang Y; Zhang Y; Chen D; Wu Z; Xiao L; Chang AH; Huang H; Zhao K
    Biol Blood Marrow Transplant; 2019 Jun; 25(6):1092-1098. PubMed ID: 30769193
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Derlin T; Schultze-Florey C; Werner RA; Möhn N; Skripuletz T; David S; Beutel G; Eder M; Ross TL; Bengel FM; Ganser A; Koenecke C
    Ann Nucl Med; 2021 Jan; 35(1):132-138. PubMed ID: 33174144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of baseline and early response FDG-PET/CT in patients with refractory and relapsed aggressive B-cell lymphoma undergoing CAR-T cell therapy.
    Georgi TW; Kurch L; Franke GN; Jentzsch M; Schwind S; Perez-Fernandez C; Petermann N; Merz M; Metzeler K; Borte G; Hoffmann S; Herling M; Denecke T; Kluge R; Sabri O; Platzbecker U; Vučinić V
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6131-6138. PubMed ID: 36662305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
    Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
    Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of FDG PET/CT in Patients With Lymphoma Treated With Chimeric Antigen Receptor T-Cell Therapy: Current Concepts.
    Murad V; Kohan A; Ortega C; Prica A; Veit-Haibach P; Metser U
    AJR Am J Roentgenol; 2024 Mar; 222(3):e2330301. PubMed ID: 38054958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion.
    Cohen D; Beyar-Katz O; Even-Sapir E; Perry C
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2447-2449. PubMed ID: 35146579
    [No Abstract]   [Full Text] [Related]  

  • 9. Early Hyperprogression of Lymphoma Detected by 18 F-FDG PET/CT After Chimeric Antigen Receptor T-Cell Therapy.
    He L; Deng Y; Deng Y; Xie H; Zhang W
    Clin Nucl Med; 2023 Mar; 48(3):256-258. PubMed ID: 36634320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary Breast Lymphoma Mimicking Metastatic Breast Cancer on 18F-FDG PET-CT.
    Usmani S; Albader FL; Marafi F; Elhaggracy RS
    J Pak Med Assoc; 2022 Jun; 72(6):1241-1242. PubMed ID: 35751349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Evaluation of Immunotherapy Response in Lymphoma Patients by 18F-FDG PET/CT: A Literature Overview.
    Ferrari C; Maggialetti N; Masi T; Nappi AG; Santo G; Niccoli Asabella A; Rubini G
    J Pers Med; 2021 Mar; 11(3):. PubMed ID: 33803667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy.
    de Boer JW; Pennings ERA; Kleinjan A; van Doesum JA; Spanjaart AM; Mutsaers PGNJ; Jak M; van der Poel MWM; Kuipers MT; Adam JA; Diepstra A; Koens L; van Dorp S; Vermaat JSP; Niezink AGH; Kersten MJ; van Meerten T
    Blood Adv; 2023 Nov; 7(21):6710-6716. PubMed ID: 37639324
    [No Abstract]   [Full Text] [Related]  

  • 13. New Onset of Tuberculosis Complicating FDG PET/CT Evaluation in Patient With Recent Chimeric Antigen Receptor T-Cell Therapy.
    Wang G; Yang X; Wang H; Wang W; Yang J
    Clin Nucl Med; 2023 Jul; 48(7):647-649. PubMed ID: 37083630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [
    Cohen D; Luttwak E; Beyar-Katz O; Hazut Krauthammer S; Bar-On Y; Amit O; Gold R; Perry C; Avivi I; Ram R; Even-Sapir E
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):953-962. PubMed ID: 34480603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A rare case of Diffuse Large B-Cell Lymphoma of the Prostate on 18F-FDG PET-CT.
    Usmani S; Ahmed DAT; Hamadah A; Al Kandari F
    J Pak Med Assoc; 2021 Jan; 71(1(B)):388-389. PubMed ID: 35157690
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic impact of total metabolic tumor volume in large B-cell lymphoma patients receiving CAR T-cell therapy.
    Iacoboni G; Simó M; Villacampa G; Catalá E; Carpio C; Díaz-Lagares C; Vidal-Jordana Á; Bobillo S; Marín-Niebla A; Pérez A; Jiménez M; Abrisqueta P; Bosch F; Barba P
    Ann Hematol; 2021 Sep; 100(9):2303-2310. PubMed ID: 34236497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT.
    Breen WG; Hathcock MA; Young JR; Kowalchuk RO; Bansal R; Khurana A; Bennani NN; Paludo J; Villasboas Bisneto JC; Wang Y; Ansell SM; Peterson JL; Johnston PB; Lester SC; Lin Y
    J Hematol Oncol; 2022 Mar; 15(1):36. PubMed ID: 35346315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on
    Winkelmann M; Rejeski K; Unterrainer M; Schmidt C; Ruzicka M; Ricke J; Rudelius M; Subklewe M; Kunz WG
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1692-1693. PubMed ID: 32814980
    [No Abstract]   [Full Text] [Related]  

  • 19. 18F-FDG PET/CT in the diagnosis of an extranodal relapse of diffuse large B-cell lymphoma (DLBCL): a clinical case with a literature review.
    Chaushev B; Micheva I; Mechmed M; Balev B; Bocheva Y; Ivanova D; Krasnaliev I; Lozanova R; Klisarova A; Bochev P; Dancheva J
    Nucl Med Rev Cent East Eur; 2016; 19(B):11-13. PubMed ID: 27813622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-[18F]FDG-PET/CT for early response and brain metabolic pattern assessment after CAR-T cell therapy in a diffuse large B cell lymphoma patient with ICANS.
    Paccagnella A; Farolfi A; Casadei B; Garibotto V; Zinzani P; Fanti S
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1090-1091. PubMed ID: 34550427
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.